FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

An FDA advisory committee has recommended adding six specific peptides to the list of ingredients that specialty compounding pharmacies can legally use. The list includes BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. This non-binding vote concludes a two-day hearing that highlighted a significant divide between agency scientists and the appointed panel members. The committee rejected a seventh peptide, emideltide, because of insufficient clinical evidence.

FDA staff scientists had expressed unanimous opposition to these additions. They pointed to a lack of clinical trial data, the risk of batch-to-batch inconsistency, and the potential for harmful immune reactions. Conversely, committee members who voted in favor of the proposal argued that allowing regulated production could move patients away from the current online black market. Many consumers currently purchase these compounds as unregulated research chemicals, where there is no medical oversight and no verification of the ingredients.

While this recommendation suggests a shift toward wider access, it does not mean these peptides are now FDA-approved or classified as standard safe medicine. These compounds remain outside the traditional clinical trial process. Inclusion on the compounding list would allow licensed pharmacies to prepare the medications upon a doctor's prescription, provided they follow requirements regarding ingredient sourcing and contamination testing.

These custom-mixed products will still lack the long-term safety tracking and formal labeling required for standard pharmaceuticals. The recommendation now moves to the FDA for final review. The agency must examine the meeting records and public comments before issuing proposed rules. This process typically spans a year, though HHS Secretary Robert F. Kennedy Jr. has previously expressed support for expanding access to these peptides, which could influence the timeline.

This decision carries implications for the wellness and telehealth sectors, which see increased business potential in offering these treatments. Critics from the medical community warn that patients may incorrectly view this inclusion as an official seal of safety. For now, the future of these six peptides hinges on the final decision from the agency's executive leadership.